NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 07 10:40AM ET
5.72
Dollar change
+0.07
Percentage change
1.15
%
Index- P/E- EPS (ttm)-2.17 Insider Own35.25% Shs Outstand8.70M Perf Week-5.54%
Market Cap49.74M Forward P/E- EPS next Y-1.77 Insider Trans0.14% Shs Float5.63M Perf Month-23.60%
Enterprise Value14.50M PEG- EPS next Q-0.59 Inst Own26.22% Short Float4.83% Perf Quarter-49.15%
Income-18.67M P/S5.34 EPS this Y0.77% Inst Trans125.10% Short Ratio0.94 Perf Half Y144.23%
Sales9.31M P/B1.44 EPS next Y11.52% ROA-80.17% Short Interest0.27M Perf YTD144.23%
Book/sh3.98 P/C1.41 EPS next 5Y4.31% ROE-93.42% 52W High20.63 -72.30% Perf Year-63.94%
Cash/sh4.05 P/FCF- EPS past 3/5Y52.23% 56.66% ROIC-53.91% 52W Low1.80 217.50% Perf 3Y-43.97%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility10.00% 7.76% Perf 5Y-92.23%
Dividend TTM- EV/Sales1.56 EPS Y/Y TTM-25.82% Oper. Margin-224.91% ATR (14)0.56 Perf 10Y-99.99%
Dividend Ex-Date- Quick Ratio9.78 Sales Y/Y TTM46.26% Profit Margin-200.58% RSI (14)33.42 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio9.78 EPS Q/Q-38.01% SMA20-15.89% Beta-0.82 Target Price15.83
Payout- Debt/Eq0.00 Sales Q/Q-18.31% SMA50-27.75% Rel Volume1.28 Prev Close5.65
Employees15 LT Debt/Eq0.00 EarningsMay 12 BMO SMA200-26.66% Avg Volume289.10K Price5.72
IPOOct 17, 2003 Option/ShortNo / Yes EPS/Sales Surpr.10.87% 33.62% Trades Volume81,915 Change1.15%
Date Action Analyst Rating Change Price Target Change
Mar-13-25Upgrade Chardan Capital Markets Neutral → Buy $14
Dec-17-24Downgrade H.C. Wainwright Buy → Neutral
Dec-11-24Downgrade Morgan Stanley Overweight → Underweight
Dec-11-24Downgrade Chardan Capital Markets Buy → Neutral
Dec-10-24Downgrade D. Boral Capital Buy → Hold
Dec-06-24Initiated ROTH MKM Buy $45
Dec-05-24Initiated H.C. Wainwright Buy $42
Sep-18-24Initiated Chardan Capital Markets Buy $55
Jul-26-24Initiated Morgan Stanley Overweight $35
Feb-15-24Initiated Canaccord Genuity Buy $50
Jun-10-25 08:00AM
May-12-25 09:15AM
08:00AM
May-07-25 08:00AM
Apr-02-25 07:00AM
02:34PM Loading…
Mar-31-25 02:34PM
Mar-25-25 08:00AM
Mar-22-25 11:00AM
02:55AM
Mar-19-25 04:27PM
Mar-18-25 04:48AM
Mar-17-25 08:00AM
07:28AM
Mar-14-25 11:25AM
Mar-10-25 04:05PM
02:09PM Loading…
Feb-19-25 02:09PM
Jan-31-25 08:00AM
Jan-29-25 08:00AM
Dec-12-24 07:45AM
07:00AM
Dec-11-24 07:16AM
Dec-10-24 11:37AM
07:00AM
Nov-28-24 07:17AM
Nov-27-24 07:00AM
Nov-13-24 08:00AM
Nov-12-24 07:00AM
Nov-08-24 09:55AM
Nov-07-24 08:30AM
Nov-04-24 08:00AM
08:00AM Loading…
Oct-29-24 08:00AM
Oct-15-24 08:00AM
Oct-04-24 04:49PM
Oct-02-24 08:00AM
Sep-26-24 08:00AM
Sep-20-24 03:37AM
Aug-27-24 08:30AM
Aug-22-24 08:00AM
Aug-12-24 08:00AM
Aug-04-24 09:03AM
Jul-30-24 08:00AM
Jul-29-24 08:00AM
Jul-17-24 08:00AM
07:00AM
Jul-16-24 07:00AM
Jul-11-24 08:51AM
Jul-10-24 10:52AM
Jun-28-24 06:50AM
Jun-24-24 08:00AM
Jun-11-24 08:00AM
May-20-24 10:09AM
08:00AM
May-15-24 09:54AM
08:00AM
Apr-03-24 07:00AM
Apr-02-24 07:00AM
Apr-01-24 08:00AM
Mar-28-24 04:05PM
08:30AM
Mar-05-24 08:00AM
Feb-21-24 08:00AM
Feb-20-24 10:22AM
Feb-12-24 08:00AM
Feb-07-24 08:30AM
07:00AM
Feb-06-24 07:00AM
Feb-05-24 08:00AM
Jan-10-24 07:00AM
Jan-09-24 07:00AM
Jan-05-24 08:00AM
Nov-13-23 07:00AM
Oct-30-23 11:21AM
Oct-25-23 02:50PM
Oct-24-23 07:00AM
Oct-18-23 07:00AM
Oct-05-23 07:00AM
Sep-18-23 10:40AM
Sep-05-23 07:00AM
Aug-21-23 08:16AM
Aug-15-23 04:01PM
Mar-30-23 07:00AM
Dec-16-22 06:30AM
Dec-05-22 06:30AM
Dec-01-22 07:55AM
Nov-17-22 05:20PM
Nov-14-22 04:01PM
06:30AM
Oct-25-22 06:30AM
Aug-17-22 08:52AM
Aug-11-22 06:48PM
Jul-26-22 07:30AM
Jun-23-22 07:30AM
May-20-22 08:10AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 04:05PM
May-04-22 07:20AM
Apr-18-22 10:42AM
09:20AM
Apr-11-22 07:20AM
CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ELDER WILLIAM ROBERTCFO, GC & SecretaryMay 14 '25Buy8.464,23335,8115,500May 14 04:11 PM
ELDER WILLIAM ROBERTCFO & GCAug 27 '24Buy18.161,00018,1601,267Aug 27 04:09 PM